Jerel M. Ezell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jerel M. Ezell has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Edward M. Zoratti
Center for Allergy, Asthma and Immunology Research, Henry Ford Hospital, Detroit, Michigan; Division of Allergy and Immunology, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan
6 shared publicationsMai T. Pho
Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, USA
6 shared publicationsSuzanne Havstad
Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan; Center for Allergy, Asthma and Immunology Research, Henry Ford Hospital, Detroit, Michigan
6 shared publicationsChristine Cole Johnson
Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan; Center for Allergy, Asthma and Immunology Research, Henry Ford Hospital, Detroit, Michigan
5 shared publicationsDennis R. Ownby
Center for Allergy, Asthma and Immunology Research, Henry Ford Hospital, Detroit, Michigan; Division of Allergy and Immunology, Department of Pediatrics, Georgia Regents University, Augusta, Georgia
5 shared publicationsElizabeth C. Chase
5 shared publications
Latest Publications
- Open Access
- 12 August 2025
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 69 (5) , 108047
Understanding the Opioid Epidemic as an Environmental Injustice
- 12 August 2025
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 69 (5) , 108047
Open AccessUnderstanding the Opioid Epidemic as an Environmental Injustice
- Open Access
- 30 May 2025
- Published by SAGE Publications in Science Communication
- Vol. 48 (4) , 547-563
Reimagining the Role of Communication in Medical Consensus to Address Medical Mistrust and Disinformation
Medical consensus is a critical element in deriving and substantiating evidence-based approaches to guide patient communication and care delivery. However, in recent years, mistrust in medicine—and in science more broadly—has deepened, driven in part by the recent politicization of public health guidance and the spread of disinformation, as well as by historically siloed and opaque public engagement practices. There has been limited critical analysis of the social processes that shape medical consensus and how these processes intersect with contemporary public attitudes and guideline adherence. Here, we discuss the intricate sociological history of medical consensus-making and its broad and deepening challenges. We further propose pathways toward more inclusive, transparent, and effective consensus-building practices, providing recommendations for a new Public Medicine Consensus framework.
- 30 May 2025
- Published by SAGE Publications in Science Communication
- Vol. 48 (4) , 547-563
Open AccessReimagining the Role of Communication in Medical Consensus to Address Medical Mistrust and Disinformation
Medical consensus is a critical element in deriving and substantiating evidence-based approaches to guide patient communication and care delivery. However, in recent years, mistrust in medicine—and in science more broadly—has deepened, driven in part by the recent politicization of public health guidance and the spread of disinformation, as well as by historically siloed and opaque public engagement practices. There has been limited critical analysis of the social processes that shape medical consensus and how these processes intersect with contemporary public attitudes and guideline adherence. Here, we discuss the intricate sociological history of medical consensus-making and its broad and deepening challenges. We further propose pathways toward more inclusive, transparent, and effective consensus-building practices, providing recommendations for a new Public Medicine Consensus framework.
- Open Access
- 15 May 2025
- Published by Elsevier in The Lancet Planetary Health
- Vol. 9 (6) , e449-e450
Property insurance bluelining as a social determinant of health
- 15 May 2025
- Published by Elsevier in The Lancet Planetary Health
- Vol. 9 (6) , e449-e450
Open AccessProperty insurance bluelining as a social determinant of health
- Open Access
- 16 September 2024
- Published by Springer Nature in International Journal of Mental Health and Addiction
- Vol. 23 (6) , 4612-4653
A Scoping Review of the Utilization of Opioid Use Treatment, Harm Reduction, and Culturally Tailored Interventions Among Racial/Ethnic Minorities in the United States
As part of a multilayered scoping review, we assessed literature on prevention and management interventions for racial/ethnic minorities in the United States (US) who non-medically use prescription opioids and/or who use illicit opioids such as heroin. The review specifically focused on access to and uptake of medications for opioid use disorder (MOUD) and harm reduction resources. We conducted a scoping review of peer-reviewed literature and governmental reports published between January 2000 and August 2024 on patterns of access to, and acceptability and utilization of, overdose prevention and opioid use management resources among racial/ethnic minorities in the US. Searches were conducted on Cochrane, PubMed, Embase, and Google Scholar, with us examining studies on the uptake of MOUD, such as buprenorphine and methadone, syringe services programs (SSPs), safe consumption sites, and harm reduction resources like naloxone (used to reverse overdoses) and fentanyl test strips (used to test for the presence of fentanyl in drug supplies). Additionally, we sought to identify and describe existing interventions for opioid use prevention and management that have expressly incorporated cultural adaptations related to racial/ethnic minorities’ specific needs and preferences in an effort to improve participants' sense of salience and acceptability and thus enhance utilization. We further endeavored to leverage this scoping review towards the development of research and intervention guidelines contoured to improve future scholarship and programming with these populations. The existing evidence suggests that racial/ethnic minorities in the US, specifically Black individuals, have diminished access to and/or utilization of preventive and management resources and amenities such as buprenorphine and naloxone, owing to structural deficits, provider bias, socioeconomic obstacles, geographic barriers, and communal stigma and distrust. Black individuals, relative to White individuals, also appear less likely to report using SSPs to obtain syringes and related resources, but across racial groups, those who used SSPs were more likely to be trained in, possess, and/or use naloxone. Further, there have been very few culturally tailored interventions for harm reduction or MOUD; there were limited data across the reviewed works on Native American/Indigenous or Asian populations; and the broader body of literature lacks methodological rigor. We close by proposing a cultural humility-focused model for better meeting the complex needs of these populations through research and primary and secondary intervention.
- 16 September 2024
- Published by Springer Nature in International Journal of Mental Health and Addiction
- Vol. 23 (6) , 4612-4653
Open AccessA Scoping Review of the Utilization of Opioid Use Treatment, Harm Reduction, and Culturally Tailored Interventions Among Racial/Ethnic Minorities in the United States
As part of a multilayered scoping review, we assessed literature on prevention and management interventions for racial/ethnic minorities in the United States (US) who non-medically use prescription opioids and/or who use illicit opioids such as heroin. The review specifically focused on access to and uptake of medications for opioid use disorder (MOUD) and harm reduction resources. We conducted a scoping review of peer-reviewed literature and governmental reports published between January 2000 and August 2024 on patterns of access to, and acceptability and utilization of, overdose prevention and opioid use management resources among racial/ethnic minorities in the US. Searches were conducted on Cochrane, PubMed, Embase, and Google Scholar, with us examining studies on the uptake of MOUD, such as buprenorphine and methadone, syringe services programs (SSPs), safe consumption sites, and harm reduction resources like naloxone (used to reverse overdoses) and fentanyl test strips (used to test for the presence of fentanyl in drug supplies). Additionally, we sought to identify and describe existing interventions for opioid use prevention and management that have expressly incorporated cultural adaptations related to racial/ethnic minorities’ specific needs and preferences in an effort to improve participants' sense of salience and acceptability and thus enhance utilization. We further endeavored to leverage this scoping review towards the development of research and intervention guidelines contoured to improve future scholarship and programming with these populations. The existing evidence suggests that racial/ethnic minorities in the US, specifically Black individuals, have diminished access to and/or utilization of preventive and management resources and amenities such as buprenorphine and naloxone, owing to structural deficits, provider bias, socioeconomic obstacles, geographic barriers, and communal stigma and distrust. Black individuals, relative to White individuals, also appear less likely to report using SSPs to obtain syringes and related resources, but across racial groups, those who used SSPs were more likely to be trained in, possess, and/or use naloxone. Further, there have been very few culturally tailored interventions for harm reduction or MOUD; there were limited data across the reviewed works on Native American/Indigenous or Asian populations; and the broader body of literature lacks methodological rigor. We close by proposing a cultural humility-focused model for better meeting the complex needs of these populations through research and primary and secondary intervention.
- 10 May 2024
- Published by Elsevier in Social Science & Medicine
- Vol. 351, 116947
The Health Disparities Research Industrial Complex: Remastered
- 10 May 2024
- Published by Elsevier in Social Science & Medicine
- Vol. 351, 116947
The Health Disparities Research Industrial Complex: Remastered
- 22 April 2024
- Published by Wiley in Drug and Alcohol Review
- Vol. 43 (5) , 1143-1159
Opioid use, prescribing and fatal overdose patterns among racial/ethnic minorities in the United States: A scoping review and conceptual risk environment model
Issues: To date, there has been no synthesis of research addressing the scale and nuances of the opioid epidemic in racial/ethnic minority populations in the United States that considers the independent and joint impacts of dynamics such as structural disadvantage, provider bias, health literacy, cultural norms and various other risk factors.Approach: Using the “risk environment” framework, we conducted a scoping review on PubMed, Embase and Google Scholar of peer‐reviewed literature and governmental reports published between January 2000 and February 2024 on the nature and scale of opioid use, opioid prescribing patterns, and fatal overdoses among racial/ethnic minorities in the United States, while also examining macro, meso and individual‐level risk factors.Key Findings: Results from this review illuminate a growing, but fragmented, literature lacking standardisation in racial/ethnic classification and case reporting, specifically in regards to Indigenous and Asian subpopulations. This literature broadly illustrates racial/ethnic minorities' increasing nonmedical use of opioids, heightened burdens of fatal overdoses, specifically in relation to polydrug use and synthetic opioids, with notable elevations among Black/Latino subgroups, in addition uneven opioid prescribing patterns. Moreover, the literature implicates a variety of unique risk environments corresponding to dynamics such as residential segregation, provider bias, overpolicing, acculturative stress, patient distrust, and limited access to mental health care services and drug treatment resources, including medications for opioid use disorder.Implications: There has been a lack of rigorous, targeted study on racial/ethnic minorities who use opioids, but evidence highlights burgeoning increases in usage, especially polydrug/synthetic opioid use, and disparities in prescriptions and fatal overdose risk‐phenomena tied to multi‐level forms of entrenched disenfranchisement.Conclusion: There is a need for further research on the complex, overlapping risk environments of racial/ethnic minorities who use opioids, including deeper inclusion of Indigenous and Asian individuals, and efforts to generate greater methodological synergies in population classification and reporting guidelines.
- 22 April 2024
- Published by Wiley in Drug and Alcohol Review
- Vol. 43 (5) , 1143-1159
Opioid use, prescribing and fatal overdose patterns among racial/ethnic minorities in the United States: A scoping review and conceptual risk environment model
Issues: To date, there has been no synthesis of research addressing the scale and nuances of the opioid epidemic in racial/ethnic minority populations in the United States that considers the independent and joint impacts of dynamics such as structural disadvantage, provider bias, health literacy, cultural norms and various other risk factors.Approach: Using the “risk environment” framework, we conducted a scoping review on PubMed, Embase and Google Scholar of peer‐reviewed literature and governmental reports published between January 2000 and February 2024 on the nature and scale of opioid use, opioid prescribing patterns, and fatal overdoses among racial/ethnic minorities in the United States, while also examining macro, meso and individual‐level risk factors.Key Findings: Results from this review illuminate a growing, but fragmented, literature lacking standardisation in racial/ethnic classification and case reporting, specifically in regards to Indigenous and Asian subpopulations. This literature broadly illustrates racial/ethnic minorities' increasing nonmedical use of opioids, heightened burdens of fatal overdoses, specifically in relation to polydrug use and synthetic opioids, with notable elevations among Black/Latino subgroups, in addition uneven opioid prescribing patterns. Moreover, the literature implicates a variety of unique risk environments corresponding to dynamics such as residential segregation, provider bias, overpolicing, acculturative stress, patient distrust, and limited access to mental health care services and drug treatment resources, including medications for opioid use disorder.Implications: There has been a lack of rigorous, targeted study on racial/ethnic minorities who use opioids, but evidence highlights burgeoning increases in usage, especially polydrug/synthetic opioid use, and disparities in prescriptions and fatal overdose risk‐phenomena tied to multi‐level forms of entrenched disenfranchisement.Conclusion: There is a need for further research on the complex, overlapping risk environments of racial/ethnic minorities who use opioids, including deeper inclusion of Indigenous and Asian individuals, and efforts to generate greater methodological synergies in population classification and reporting guidelines.
- Open Access
- 8 April 2024
- Published by Springer Nature in Harm Reduction Journal
- Vol. 21 (1) , 1-15
How do people who use opioids express their qualities and capacities? An assessment of attitudes, behaviors, and opportunities
People who nonmedically use drugs (PWUD) face intricate social issues that suppress self-actualization, communal integration, and overall health and wellness. “Strengths-based” approaches, an under-used pedagogy and practice in addiction medicine, underscore the significance of identifying and recognizing the inherent and acquired skills, attributes, and capacities of PWUD. A strengths-based approach engenders client affirmation and improves their capacity to reduce drug use-related harms by leveraging existing capabilities. Exploring this paradigm, we conducted and analyzed interviews with 46 PWUD who were clients at syringe services programs in New York City and rural southern Illinois, two areas with elevated rates of opioid-related morbidity and mortality, to assess respondents’ perceived strengths. We located two primary thematic modalities in which strengths-based ethos is expressed: individuals (1) being and advocate and resource for harm reduction knowledge and practices and (2) engaging in acts of continuous self-actualization. These dynamics demonstrate PWUD strengths populating and manifesting in complex ways that both affirm and challenge humanist and biomedical notions of individual agency, as PWUD refract enacted, anticipated, and perceived stigmas. In conclusion, programs that blend evidence-based, systems-level interventions on drug use stigma and disenfranchisement with meso and micro-level strengths-based interventions that affirm and leverage personal identity, decision-making capacity, and endemic knowledge may help disrupt health promotion cleavages among PWUD.
- 8 April 2024
- Published by Springer Nature in Harm Reduction Journal
- Vol. 21 (1) , 1-15
Open AccessHow do people who use opioids express their qualities and capacities? An assessment of attitudes, behaviors, and opportunities
People who nonmedically use drugs (PWUD) face intricate social issues that suppress self-actualization, communal integration, and overall health and wellness. “Strengths-based” approaches, an under-used pedagogy and practice in addiction medicine, underscore the significance of identifying and recognizing the inherent and acquired skills, attributes, and capacities of PWUD. A strengths-based approach engenders client affirmation and improves their capacity to reduce drug use-related harms by leveraging existing capabilities. Exploring this paradigm, we conducted and analyzed interviews with 46 PWUD who were clients at syringe services programs in New York City and rural southern Illinois, two areas with elevated rates of opioid-related morbidity and mortality, to assess respondents’ perceived strengths. We located two primary thematic modalities in which strengths-based ethos is expressed: individuals (1) being and advocate and resource for harm reduction knowledge and practices and (2) engaging in acts of continuous self-actualization. These dynamics demonstrate PWUD strengths populating and manifesting in complex ways that both affirm and challenge humanist and biomedical notions of individual agency, as PWUD refract enacted, anticipated, and perceived stigmas. In conclusion, programs that blend evidence-based, systems-level interventions on drug use stigma and disenfranchisement with meso and micro-level strengths-based interventions that affirm and leverage personal identity, decision-making capacity, and endemic knowledge may help disrupt health promotion cleavages among PWUD.
- Open Access
- 1 February 2024
- Published by Taylor & Francis in Medical Education Online
- Vol. 29 (1) , 2307710
Rethinking and Reinforcing Cultural Humility Against the Culture Wars: A Framework For Addressing Receptivity to Diversity Initiatives
- 1 February 2024
- Published by Taylor & Francis in Medical Education Online
- Vol. 29 (1) , 2307710
Open AccessRethinking and Reinforcing Cultural Humility Against the Culture Wars: A Framework For Addressing Receptivity to Diversity Initiatives
- 1 February 2024
- Published by American Psychological Association (APA) in Qualitative Psychology
- Vol. 11 (1) , 5-24
Black girls don’t cry? Mental health, gender, and violence on the racialized periphery.
- 1 February 2024
- Published by American Psychological Association (APA) in Qualitative Psychology
- Vol. 11 (1) , 5-24
Black girls don’t cry? Mental health, gender, and violence on the racialized periphery.
- 4 December 2023
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 66 (3) , 568-572
Drug Use and Artificial Intelligence: Weighing Concerns and Possibilities for Prevention
- 4 December 2023
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 66 (3) , 568-572
Drug Use and Artificial Intelligence: Weighing Concerns and Possibilities for Prevention